184 related articles for article (PubMed ID: 22234518)
21. Basal-like breast cancer defined by FOXC1 expression offers superior prognostic value: a retrospective immunohistochemical study.
Ray PS; Bagaria SP; Wang J; Shamonki JM; Ye X; Sim MS; Steen S; Qu Y; Cui X; Giuliano AE
Ann Surg Oncol; 2011 Dec; 18(13):3839-47. PubMed ID: 21424368
[TBL] [Abstract][Full Text] [Related]
22. P-cadherin and vimentin are useful basal markers in breast cancers.
Tsang JY; Au SK; Ni YB; Shao MM; Siu WM; Hui SW; Chan SK; Chan KW; Kwok YK; Chan KF; Tse GM
Hum Pathol; 2013 Dec; 44(12):2782-91. PubMed ID: 24139214
[TBL] [Abstract][Full Text] [Related]
23. Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.
Pintens S; Neven P; Drijkoningen M; Van Belle V; Moerman P; Christiaens MR; Smeets A; Wildiers H; Vanden Bempt I
J Clin Pathol; 2009 Jul; 62(7):624-8. PubMed ID: 19561231
[TBL] [Abstract][Full Text] [Related]
24. Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis.
Del Casar JM; Martín A; García C; Corte MD; Alvarez A; Junquera S; González LO; Bongera M; García-Muñiz JL; Allende MT; Vizoso F
Eur J Obstet Gynecol Reprod Biol; 2008 Dec; 141(2):147-52. PubMed ID: 18768247
[TBL] [Abstract][Full Text] [Related]
25. Contemplating chemosensitivity of basal-like breast cancer based on BRCA1 dysfunction.
Ohta T; Wu W; Koike A; Asakawa H; Koizumi H; Fukuda M
Breast Cancer; 2009; 16(4):268-74. PubMed ID: 19459031
[TBL] [Abstract][Full Text] [Related]
26. What is triple-negative breast cancer?
Irvin WJ; Carey LA
Eur J Cancer; 2008 Dec; 44(18):2799-805. PubMed ID: 19008097
[TBL] [Abstract][Full Text] [Related]
27. Morphological characteristics of basal-like subtype of breast carcinoma with special reference to cytopathological features.
Ishihara A; Tsuda H; Kitagawa K; Yoneda M; Shiraishi T
Breast Cancer; 2009; 16(3):179-85. PubMed ID: 19466513
[TBL] [Abstract][Full Text] [Related]
28. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
30. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
[TBL] [Abstract][Full Text] [Related]
31. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer.
Collins LC; Marotti JD; Gelber S; Cole K; Ruddy K; Kereakoglow S; Brachtel EF; Schapira L; Come SE; Winer EP; Partridge AH
Breast Cancer Res Treat; 2012 Feb; 131(3):1061-6. PubMed ID: 22080245
[TBL] [Abstract][Full Text] [Related]
32. EGFR overexpression relates to triple negative profile and poor prognosis in breast cancer patients in Tunisia.
Kallel I; Khabir A; Boujelbene N; Abdennadher R; Daoud J; Frikha M; Aifa S; Sallemi-Boudawara T; Rebaï A
J Recept Signal Transduct Res; 2012 Jun; 32(3):142-9. PubMed ID: 22394363
[TBL] [Abstract][Full Text] [Related]
33. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
Toyama T; Yamashita H; Kondo N; Okuda K; Takahashi S; Sasaki H; Sugiura H; Iwase H; Fujii Y
BMC Cancer; 2008 Oct; 8():309. PubMed ID: 18950515
[TBL] [Abstract][Full Text] [Related]
34. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
35. Frequency of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from Trentino, North East Italy.
Giuliani S; Leonardi E; Aldovini D; Bernardi D; Pellegrini M; Soli F; Ferro A; Dalla Palma P; Decarli N; Barbareschi M
Pathologica; 2012 Jun; 104(3):93-7. PubMed ID: 22931039
[TBL] [Abstract][Full Text] [Related]
36. Directed therapy of subtypes of triple-negative breast cancer.
Carey LA
Oncologist; 2011; 16 Suppl 1():71-8. PubMed ID: 21278443
[TBL] [Abstract][Full Text] [Related]
37. "Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.
Nanda R
Semin Oncol; 2011 Apr; 38(2):254-62. PubMed ID: 21421115
[TBL] [Abstract][Full Text] [Related]
38. Triple-negative breast cancer: unique biology and its management.
Maegawa RO; Tang SC
Cancer Invest; 2010 Oct; 28(8):878-83. PubMed ID: 20839950
[TBL] [Abstract][Full Text] [Related]
39. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes.
Rakha EA; Elsheikh SE; Aleskandarany MA; Habashi HO; Green AR; Powe DG; El-Sayed ME; Benhasouna A; Brunet JS; Akslen LA; Evans AJ; Blamey R; Reis-Filho JS; Foulkes WD; Ellis IO
Clin Cancer Res; 2009 Apr; 15(7):2302-10. PubMed ID: 19318481
[TBL] [Abstract][Full Text] [Related]
40. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.
Anders CK; Hsu DS; Broadwater G; Acharya CR; Foekens JA; Zhang Y; Wang Y; Marcom PK; Marks JR; Febbo PG; Nevins JR; Potti A; Blackwell KL
J Clin Oncol; 2008 Jul; 26(20):3324-30. PubMed ID: 18612148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
